Abstract
Behçet disease is the only primary vasculitis that affects both arteries and veins of any size. We present our treatment protocol in disease with vascular involvement in seven pediatric patients. All seven patients met the international criteria for the disease before the age of 16 years. Only one was a girl. The vascular involvement was as follows: Two patients had superficial vein thrombosis, two patients had atrial or ventricular thrombosis, one had arterial involvement with pulmonary aneurysms, and two had thrombosis of the venous sinuses in the central nervous system. The median duration of vascular involvement was 4 months (range 3–24 months) after the diagnosis of BD and was concomitant with diagnosis in three patients. All received colchicine and steroids. The ones with thrombosis in the venous system received additional azathioprine, whereas those with pulmonary arterial or cardiac involvement initially received cyclophosphamide for 150–180 mg/kg total dose (IV or oral) and then were switched to azathioprine for a further 6 months. All except the patient with pulmonary arterial involvement received a course of anticoagulation treatment as well. These patients have been followed up for a period of at least 18 months and so far are free of vascular relapses. One has developed a severe uveitis necessitating further therapy. In conclusion, features of vascular involvement should be carefully sought for in patients with Behçet disease. Effective management has enabled disease-free survival in the presented patients.
Similar content being viewed by others
References
Ahn JK, Lee YS, Jeon CH et al (2008) Treatment of venous thrombosis associated with Behçet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 27:201–205
Akpolat T, Akkoyunlu M, Akpolat I et al (2001) Renal Behçet’s disease: a cumulative analysis. Semin Arthritis Rheum 30(4):281–287
Behcet H (1937) Uber rezidivierende aphtose, durch ein virus verursachte Geschwure am Mund, am Auge and an den genitalien. Dermatol Wochenschr 105:1152–1157
Espinosa G, Font J, Tassies D et al (2002) Vascular involvement in Behçet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 112:37–43
Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67(12):1656–1662
(1990) Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 335:1070–1080
Kobayashi M, Ito M, Nakagawa A, Matsushita M (2000) Neutrophil and endothelial cell activation in the vasa vasorum in vascular-Behçet disease. Histopathology 36(4):362–371
Kone-Paut I, Yurdakul S, Bahabri SA et al (1998) Clinical features in Behçet’s disease in children: an international collaborative study of 86 cases. J Pediatr 132(4):721–725
Kucukoglu RS, Kose A, Kayabalı M et al (2006) Vascular involvement in Behçet’s disease: aretrospective analysis of 2319 cases. Int J Dermatol 45:919–921
O’duffy JD (1990) Vasculitis in Behçet’s disease. Rheum Dis Clin North Am 16:423–431
Ozen S, Petty RE (2005) Behçet’s disease. In: Cassidy JT, Petty RE, Laxer RM, Lindley CB (eds) Textbook of pediatric rheumatology. Elsevier, Philadelphia, pp 561–565
Sakane T, Takeno M, Suzuki N et al (1999) Behçet’s disease. N Engl J Med 341:1284–1291
Tohme A, Aoun N, El-Rassi B et al (2003) Vascular manifestations of Behçet’s disease: eighteen cases among 140 patients. Jt Bone Spine 70:384–389
Conflict of interest
The authors do not have a financial relationship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ozen, S., Bilginer, Y., Besbas, N. et al. Behçet disease: treatment of vascular involvement in children. Eur J Pediatr 169, 427–430 (2010). https://doi.org/10.1007/s00431-009-1040-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-009-1040-y